Nutriband Inc.'s Patent, 'Abuse and Misuse Deterrent Transdermal System’ Published by the United States Patent and Trademark Office Following Recent Issuance Notice

Rhea-AI Summary

Nutriband Inc. (NASDAQ:NTRB, NTRBW) announced that the USPTO published a patent for its AVERSA™ technology aimed at preventing opioid misuse through a transdermal system. The patent, US Patent 11,246,840, was issued on February 15, 2022, and supports the development of the AVERSA Fentanyl patch. Nutriband has entered a feasibility agreement with Kindeva Drug Delivery to incorporate this technology in its lead product candidate.

Positive

• Patent US 11,246,840 enhances AVERSA technology, supporting its lead product development.
• Feasibility agreement with Kindeva Drug Delivery indicates progress in product development.

Negative

• None.

ORLANDO, FL / ACCESSWIRE / February 16, 2022 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), has announced that the United States Patent and Trademark Office (USPTO) has published its patent titled "Abuse and Misuse Deterrent Transdermal System" which is related to the Company's lead technology AVERSA™.

US Patent 11,246,840 dated Feb 15, 2022 underpins 4P Therapeutics' abuse deterrent transdermal system, AVERSA™, which uses taste aversion to address the primary routes of abuse for opioid based transdermal patches.

The company is incorporating the patent into its lead product candidate AVERSA Fentanyl for which it recently signed a feasibility agreement with Kindeva Drug Delivery.

About Nutriband Inc.

We are primarily engaged in the development of a portfolio of transdermal pharmaceutical products. Our lead product under development is an abuse deterrent fentanyl patch incorporating our AVERSA^™ abuse deterrence technology. AVERSA™ technology can be incorporated into any transdermal patch to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential.

The Company's website is www.nutriband.com. Any material contained in or derived from the Company's websites or any other website is not part of this press release.

Forward-Looking Statements

Certain statements contained in this press release, including, without limitation, statements containing the words ‘'believes,'' "anticipates," "expects" and words of similar import, constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve both known and unknown risks and uncertainties. The Company's actual results may differ materially from those anticipated in its forward-looking statements as a result of a number of factors, including those including the Company's ability to develop its proposed abuse deterrent fentanyl transdermal system and other proposed products, its ability to obtain patent protection for its abuse technology, its ability to obtain the necessary financing to develop products and conduct the necessary clinical testing, its ability to obtain Federal Food and Drug Administration approval to market any product it may develop in the United States and to obtain any other regulatory approval necessary to market any product in other countries, including countries in Europe, its ability to market any product it may develop, its ability to create, sustain, manage or forecast its growth; its ability to attract and retain key personnel; changes in the Company's business strategy or development plans; competition; business disruptions; adverse publicity and international, national and local general economic and market conditions and risks generally associated with an undercapitalized developing company, as well as the risks contained under "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in the Company's Form S-1, Form 10-K for the year ended January 31, 2020 and Forms 10-Q, and the Company's other filings with the Securities and Exchange Commission. Except as required by applicable law, we undertake no obligation to revise or update any forward-looking statements to reflect any event or circumstance that may arise after the date hereof.

For the full patent publication click the link - https://tinyurl.com/2tj48b65

For more information, contact:

Investor Relations
RedChip Companies
Dave Gentry
Dave@redchip.com
1-800-RED-CHIP (733-2447)
407-491-4498

SOURCE: Nutriband Inc.

View source version on accesswire.com:
https://www.accesswire.com/688999/Nutriband-Incs-Patent-Abuse-and-Misuse-Deterrent-Transdermal-System-Published-by-the-United-States-Patent-and-Trademark-Office-Following-Recent-Issuance-Notice

FAQ

What is Nutriband Inc.'s new patent about?

Nutriband's new patent, US Patent 11,246,840, is for an abuse deterrent transdermal system using AVERSA™ technology to address opioid misuse.

What is AVERSA Fentanyl?

AVERSA Fentanyl is Nutriband's lead product candidate that incorporates its patented abuse deterrent technology to prevent opioid misuse.

When was the patent for AVERSA technology published?

The patent for AVERSA technology was published on February 15, 2022.

What company is involved in developing AVERSA technology?

Nutriband Inc. is the company developing the AVERSA technology, specifically for its fentanyl patch.

What significance does the patent hold for Nutriband's future?

The patent signifies a critical step in developing Nutriband's lead product, enhancing its market potential and addressing opioid misuse.